Literature DB >> 20491632

Molecular structure of ionotropic glutamate receptors.

A A Kaczor1, D Matosiuk.   

Abstract

L-glutamate is the major excitatory neurotransmitter in the central nervous system (CNS). Although just a few glutamate receptor ligands have turned out to be clinically useful, primarily because of unfavorable psychotropic side effects, the glutamate system remains an attractive molecular target in the treatment of epilepsy, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, Huntington's chorea), schizophrenia, ischemia, pain, alcoholism and mood disorders. Knowledge about the structure of ionotropic glutamate receptors (iGluRs) at atomic resolution is vital for the determination of their physiological and pathological importance and, thus, for drug design. Recently, tremendous progress has been made in structure elucidation and understanding of the functioning of iGluRs. The data about general topology and modular composition of iGluRs as well as numerous crystal structures of ligand binding domains of many iGluR subtypes has been supplemented with the first molecular models of the whole receptor protein, followed by the first crystal structures of N-terminal domains and finally by the first crystal structure of the whole tetrameric iGluR. This review summarizes experimental and computational efforts to determine iGluR molecular architecture and focus on the above listed achievements of the last years. In particular, the aspects of iGluR structure which are important for drug design, like the molecular characterstics of the ligand binding sites, are depicted in detail.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20491632     DOI: 10.2174/092986710791859379

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  7 in total

1.  Discovery of a new class of ionotropic glutamate receptor antagonists by the rational design of (2S,3R)-3-(3-carboxyphenyl)-pyrrolidine-2-carboxylic acid.

Authors:  Ann M Larsen; Raminta Venskutonytė; Elena Antón Valadés; Birgitte Nielsen; Darryl S Pickering; Lennart Bunch
Journal:  ACS Chem Neurosci       Date:  2010-11-12       Impact factor: 4.418

2.  Probing for improved potency and in vivo bioavailability of excitatory amino acid transporter subtype 1 inhibitors UCPH-101 and UCPH-102: design, synthesis and pharmacological evaluation of substituted 7-biphenyl analogs.

Authors:  Mette N Erichsen; Jeanette Hansen; Josep A Ruiz; Charles S Demmer; Bjarke Abrahamsen; Jesper F Bastlund; Christoffer Bundgaard; Anders A Jensen; Lennart Bunch
Journal:  Neurochem Res       Date:  2014-02-28       Impact factor: 3.996

Review 3.  Brain-derived neurotrophic factor in urinary continence and incontinence.

Authors:  Qi-Xiang Song; Christopher J Chermansky; Lori A Birder; Longkun Li; Margot S Damaser
Journal:  Nat Rev Urol       Date:  2014-09-16       Impact factor: 14.432

4.  The Role of CNTNAP2 in Itch Sensation.

Authors:  Santosh K Mishra
Journal:  J Invest Dermatol       Date:  2021-07-24       Impact factor: 8.551

5.  in Silico investigation of the structural requirements for the AMPA receptor antagonism by quinoxaline derivatives.

Authors:  Faizul Azam; Ismaiel Mohamed Abugrain; Mohamed Hussin Sanalla; Radwan Fatahalla Elnaas; Ibrahim Abdassalam Ibn Rajab
Journal:  Bioinformation       Date:  2013-10-16

6.  Synthesis and molecular docking of novel non-competitive antagonists of GluK2 receptor.

Authors:  Agnieszka A Kaczor; Tomasz Wróbel; Christiane Kronbach; Klaus Unverferth; Tomasz Stachal; Dariusz Matosiuk
Journal:  Med Chem Res       Date:  2014-07-24       Impact factor: 1.965

7.  The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.